Ontology highlight
ABSTRACT:
SUBMITTER: Lee SJ
PROVIDER: S-EPMC2954751 | biostudies-literature | 2008 Oct
REPOSITORIES: biostudies-literature
Lee Stephanie J SJ Kukreja Manisha M Wang Tao T Giralt Sergio A SA Szer Jeffrey J Arora Mukta M Woolfrey Ann E AE Cervantes Francisco F Champlin Richard E RE Gale Robert Peter RP Halter Joerg J Keating Armand A Marks David I DI McCarthy Philip L PL Olavarria Eduardo E Stadtmauer Edward A EA Abecasis Manuel M Gupta Vikas V Khoury H Jean HJ George Biju B Hale Gregory A GA Liesveld Jane L JL Rizzieri David A DA Antin Joseph H JH Bolwell Brian J BJ Carabasi Matthew H MH Copelan Edward E Ilhan Osman O Litzow Mark R MR Schouten Harold C HC Zander Axel R AR Horowitz Mary M MM Maziarz Richard T RT
Blood 20080729 8
Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM(+)) and 900 subjects who did not receive IM before HCT (IM(-)) were analyzed. Among ...[more]